Company intelligence / Profile preview
Hemosol Inc.
Mississauga, Ontario, Canadahemosol.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
Hemosol developed blood substitute products including Hemolink, which underwent Phase II clinical trials. The company faced challenges with safety data and declared insolvency in 2005 after its market value dropped from $600 million in 2000 to $23 million by mid-2003.
- Therapeutic areas
- HematologyOncologyInfectious Diseases
- Modalities
- Blood-related protein therapeuticsCell therapeuticsOxygen therapeutics
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Hemosol Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hemosol Inc..